Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


Effects of DLC1 Deficiency on Endothelial Cell Contact Growth Inhibition and Angiosarcoma Progression.

Sánchez-Martín D, Otsuka A, Kabashima K, Ha T, Wang D, Qian X, Lowy DR, Tosato G.

J Natl Cancer Inst. 2018 Apr 1;110(4):390-399. doi: 10.1093/jnci/djx219.


Evidence for a Mesothelial Origin of Body Cavity Effusion Lymphomas.

Sanchez-Martin D, Uldrick TS, Kwak H, Ohnuki H, Polizzotto MN, Annunziata CM, Raffeld M, Wyvill KM, Aleman K, Wang V, Marshall VA, Whitby D, Yarchoan R, Tosato G.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx016.


Selection strategies for anticancer antibody discovery: searching off the beaten path.

Sánchez-Martín D, Sørensen MD, Lykkemark S, Sanz L, Kristensen P, Ruoslahti E, Álvarez-Vallina L.

Trends Biotechnol. 2015 May;33(5):292-301. doi: 10.1016/j.tibtech.2015.02.008. Epub 2015 Mar 26. Review.


Tumor-infiltrating myeloid cells activate Dll4/Notch/TGF-β signaling to drive malignant progression.

Ohnuki H, Jiang K, Wang D, Salvucci O, Kwak H, Sánchez-Martín D, Maric D, Tosato G.

Cancer Res. 2014 Apr 1;74(7):2038-49. doi: 10.1158/0008-5472.CAN-13-3118. Epub 2014 Feb 11.


In vivo selection of tumor-specific antibodies.

Sánchez-Martín D, Sanz L, Ruoslahti E, Alvarez-Vallina L.

Oncotarget. 2013 Oct;4(10):1547. No abstract available.


Basement membrane-rich organoids with functional human blood vessels are permissive niches for human breast cancer metastasis.

Fernández-Periáñez R, Molina-Privado I, Rojo F, Guijarro-Muñoz I, Alonso-Camino V, Zazo S, Compte M, Alvarez-Cienfuegos A, Cuesta AM, Sánchez-Martín D, Alvarez-Méndez AM, Sanz L, Alvarez-Vallina L.

PLoS One. 2013 Aug 8;8(8):e72957. doi: 10.1371/journal.pone.0072957. eCollection 2013.


Proteasome activator complex PA28 identified as an accessible target in prostate cancer by in vivo selection of human antibodies.

Sánchez-Martín D, Martínez-Torrecuadrada J, Teesalu T, Sugahara KN, Alvarez-Cienfuegos A, Ximénez-Embún P, Fernández-Periáñez R, Martín MT, Molina-Privado I, Ruppen-Cañás I, Blanco-Toribio A, Cañamero M, Cuesta AM, Compte M, Kremer L, Bellas C, Alonso-Camino V, Guijarro-Muñoz I, Sanz L, Ruoslahti E, Alvarez-Vallina L.

Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13791-6. doi: 10.1073/pnas.1300013110. Epub 2013 Aug 5.


CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors.

Alonso-Camino V, Sánchez-Martín D, Compte M, Nuñez-Prado N, Diaz RM, Vile R, Alvarez-Vallina L.

Mol Ther Nucleic Acids. 2013 May 21;2:e93. doi: 10.1038/mtna.2013.19.


Generation and characterization of monospecific and bispecific hexavalent trimerbodies.

Blanco-Toribio A, Sainz-Pastor N, Álvarez-Cienfuegos A, Merino N, Cuesta ÁM, Sánchez-Martín D, Bonet J, Santos-Valle P, Sanz L, Oliva B, Blanco FJ, Álvarez-Vallina L.

MAbs. 2013 Jan-Feb;5(1):70-9. doi: 10.4161/mabs.22698. Epub 2012 Dec 5.


Improved stability of multivalent antibodies containing the human collagen XV trimerization domain.

Cuesta AM, Sánchez-Martín D, Blanco-Toribio A, Villate M, Enciso-Álvarez K, Alvarez-Cienfuegos A, Sainz-Pastor N, Sanz L, Blanco FJ, Alvarez-Vallina L.

MAbs. 2012 Mar-Apr;4(2):226-32. doi: 10.4161/mabs.4.2.19140. Epub 2012 Mar 1.


Engineering human cells for in vivo secretion of antibody and non-antibody therapeutic proteins.

Sánchez-Martín D, Sanz L, Álvarez-Vallina L.

Curr Opin Biotechnol. 2011 Dec;22(6):924-30. doi: 10.1016/j.copbio.2011.03.001. Epub 2011 Mar 22.


The multicompartmental p32/gClqR as a new target for antibody-based tumor targeting strategies.

Sánchez-Martín D, Cuesta AM, Fogal V, Ruoslahti E, Alvarez-Vallina L.

J Biol Chem. 2011 Feb 18;286(7):5197-203. doi: 10.1074/jbc.M110.161927. Epub 2010 Dec 14.


Factory neovessels: engineered human blood vessels secreting therapeutic proteins as a new drug delivery system.

Compte M, Alonso-Camino V, Santos-Valle P, Cuesta AM, Sánchez-Martín D, López MR, Vicario JL, Salas C, Sanz L, Alvarez-Vallina L.

Gene Ther. 2010 Jun;17(6):745-51. doi: 10.1038/gt.2010.33. Epub 2010 Mar 25.


Lymphocyte display: a novel antibody selection platform based on T cell activation.

Alonso-Camino V, Sánchez-Martín D, Compte M, Sanz L, Alvarez-Vallina L.

PLoS One. 2009 Sep 24;4(9):e7174. doi: 10.1371/journal.pone.0007174.


In vivo tumor targeting and imaging with engineered trivalent antibody fragments containing collagen-derived sequences.

Cuesta AM, Sánchez-Martín D, Sanz L, Bonet J, Compte M, Kremer L, Blanco FJ, Oliva B, Alvarez-Vallina L.

PLoS One. 2009;4(4):e5381. doi: 10.1371/journal.pone.0005381. Epub 2009 Apr 29.


Tumor immunotherapy using gene-modified human mesenchymal stem cells loaded into synthetic extracellular matrix scaffolds.

Compte M, Cuesta AM, Sánchez-Martín D, Alonso-Camino V, Vicario JL, Sanz L, Alvarez-Vallina L.

Stem Cells. 2009 Mar;27(3):753-60. doi: 10.1634/stemcells.2008-0831.


Comment on "Production of multivalent protein binders using a self-trimerization collagen-like peptide scaffold".

Cuesta AM, Sánchez-Martín D, Sanz L, Alvarez-Vallina L.

FASEB J. 2008 Oct;22(10):3417; author reply 3417-8. doi: 10.1096/fj.08-1003LTR. No abstract available.


Long-term in vivo imaging of human angiogenesis: critical role of bone marrow-derived mesenchymal stem cells for the generation of durable blood vessels.

Sanz L, Santos-Valle P, Alonso-Camino V, Salas C, Serrano A, Vicario JL, Cuesta AM, Compte M, Sánchez-Martín D, Alvarez-Vallina L.

Microvasc Res. 2008 Apr;75(3):308-14. doi: 10.1016/j.mvr.2007.11.007. Epub 2007 Dec 15.


Supplemental Content

Loading ...
Support Center